The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global asthma therapeutics market reached a value of US$ 17.6 Billion in 2020. Looking forward, the market is expected to reach a value of US$ 19.13 Billion by 2026, expanding at a CAGR of 1.60% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Asthma therapeutics refer to various pharmaceutical drugs that are used for the treatment of asthma. Asthma is usually triggered by indoor and outdoor causative agents, including pollution, allergens and dust. These therapeutics are usually bronchodilators and anti-inflammatory drugs, which include corticosteroids, long-acting beta-agonists (LABA), methylxanthine, immunomodulators and leukotriene modifiers. A number of combination therapy drugs are also used that can be inhaled, injected, or orally administered. These drugs expand the passageway into the lungs and enable the movement of air to improve breathing. They also aid in clearing mucus from the lungs that gets coughed out with ease.
The increasing prevalence of asthma and other respiratory disorders, along with improvements in the diagnostic technologies, is one of the key factors driving the growth of the market. Furthermore, rising awareness among the masses regarding the availability of effective asthma therapeutics is also providing driving the market growth. For instance, asthmatic patients are primarily treated with inhaled corticosteroids and patients with advanced conditions or persistent asthma are treated with target-specific drugs. There is also an extensive demand for monoclonal antibodies (mAbs) that block immunoglobulin E and specific cytokines. The development of combination therapies for the treatment of respiratory diseases is acting as another growth-inducing factor. Increasing healthcare expenditures, extensive research, and development (R&D) activities in the field of medical sciences and improvements in the healthcare infrastructure are some of the other factors that are expected to drive the market further.
IMARC Group provides an analysis of the key trends in each sub-segment of the global asthma therapeutics market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on drug class, product type, treatment type and route of administration.
Breakup by Drug Class:
Breakup by Product Type:
Breakup by Treatment Type:
Breakup by Route of Administration:
Breakup by Region:
The report has also analysed the competitive landscape of the market with some of the key players being AstraZeneca, Abbott, Amgen Inc., Biogen Inc., Boehringer Ingelheim GmbH, F. Hoffmann-La Roche AG, GlaxoSmithKline plc., Merck & Co. Inc., Novartis AG, Sunovion Pharmaceuticals Inc. (Dainippon Sumitomo Pharma Co. Ltd.) and Teva Pharmaceutical Industries Ltd.
|Base Year of the Analysis||2020|
|Segment Coverage||Drug Class, Product Type, Treatment Type, Route of Administration, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||AstraZeneca, Abbott, Amgen Inc., Biogen Inc., Boehringer Ingelheim GmbH, F. Hoffmann-La Roche AG, GlaxoSmithKline plc., Merck & Co. Inc., Novartis AG, Sunovion Pharmaceuticals Inc. (Dainippon Sumitomo Pharma Co. Ltd.) and Teva Pharmaceutical Industries Ltd.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
The global asthma therapeutics market was valued at US$ 17.6 Billion in 2020.
We expect the global asthma therapeutics market to exhibit a CAGR of 1.60% during 2021-2026.
The increasing prevalence of asthma, along with continuous improvements in the diagnostic technologies, are driving the global asthma therapeutics market.
Sudden outbreak of the COVID-19 pandemic has led to the increasing adoption of asthma therapeutics as severe respiratory diseases, such as coronavirus infection, can worsen asthma symptoms.
Based on the drug class, the global asthma therapeutics market can be segmented into anti-inflammatory drugs, bronchodilators, and combination therapies. Currently, combination therapies hold the majority of the total market share.
Based on the product type, the global asthma therapeutics market has been segregated into inhalers and nebulizers where, nebulizers currently represent the largest segment.
Based on the route of administration, the global asthma therapeutics market can be segmented into inhalation, oral and parenteral. Among these, inhalation accounts for the largest market share.
On a regional level, the market has been classified into North America, Asia Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global asthma therapeutics market include AstraZeneca, Abbott, Amgen Inc., Biogen Inc., Boehringer Ingelheim GmbH, F. Hoffmann-La Roche AG, GlaxoSmithKline plc., Merck & Co. Inc., Novartis AG, Sunovion Pharmaceuticals Inc. (Dainippon Sumitomo Pharma Co. Ltd.) and Teva Pharmaceutical Industries Ltd.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at